Showing results (111-120 of 157) with videos related to
Sort By:
Pageof 16
The British Journal of Dermatology|April 5, 2011
A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trialY Poulin, N P Sanchez, A Bucko, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 8, 2017
Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trialsC Paul, L Guenther, H Torii, et al.Journal of the American Academy of Dermatology|September 25, 2001
Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasisM Lebwohl, L Drake, A Menter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 26, 2019
Itch: an under-recognized problem in psoriasisB Elewski, A F Alexis, M Lebwohl, et al.Journal of the American Academy of Dermatology|November 21, 1997
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgarisA W Lucky, T A Henderson, W H Olson, et al.Journal of Cutaneous Medicine and Surgery|May 10, 2002
Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaJ K L Tan, C Girard, A Krol, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 27, 2010
Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markersJ Aubert, P Reiniche, P Fogel, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 12, 2019
Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasisM Lebwohl, R G Langley, Y Zhu, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trialR B Warren, M Lebwohl, H Sofen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 15, 2020
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trialsL Puig, T-F Tsai, T Bhutani, et al.Pageof 16